Harnessing Natural Killer Cells in Cancer Immunotherapy: A Review of Mechanisms and Novel Therapies

by Frederique St-Pierre, Shailender Bhatia, Sunandana Chandra
Published 2021-04-01

Immunotherapy for Merkel cell carcinoma: a turning point in patient care

by Isaac S. Chan, Shailender Bhatia, Howard L. Kaufman, Evan J. Lipson
Published 2018-03-01

Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center

by Evan Hall, Jenny Zhang, Eun Jeong Kim, Grace Hwang, Gilbert Chu, Shailender Bhatia, Sunil Reddy
Published 2020-03-01

Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma

by Dirk Schadendorf, Paul Nghiem, Shailender Bhatia, Axel Hauschild, Philippe Saiag, Lisa Mahnke, Subramanian Hariharan, Howard L. Kaufman
Published 2017-10-01

Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.

by Shailender Bhatia, James Moon, Kim A Margolin, Jeffrey S Weber, Christopher D Lao, Megan Othus, Ana M Aparicio, Antoni Ribas, Vernon K Sondak
Published 2012-01-01

Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series

by Jaclyn LoPiccolo, Megan D. Schollenberger, Sumia Dakhil, Samuel Rosner, Osama Ali, William H. Sharfman, Ann W. Silk, Shailender Bhatia, Evan J. Lipson
Published 2019-07-01

Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report

by Jacob Appelbaum, David Wells, Joseph B. Hiatt, Gideon Steinbach, F. Marc Stewart, Hannah Thomas, Paul Nghiem, Raj P. Kapur, John A. Thompson, Shailender Bhatia
Published 2018-08-01

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy

by Natalie J. Miller, Candice D. Church, Steven P. Fling, Rima Kulikauskas, Nirasha Ramchurren, Michi M. Shinohara, Harriet M. Kluger, Shailender Bhatia, Lisa Lundgren, Martin A. Cheever, Suzanne L. Topalian, Paul Nghiem
Published 2018-11-01

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

by Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Céleste Lebbé, Michele Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Meliessa Hennessy, Paul Nghiem
Published 2018-01-01

Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance

by Christopher W. Lewis, Jamiluddin Qazi, Daniel S. Hippe, Kristina Lachance, Hannah Thomas, Maclean M. Cook, Ilsa Juhlin, Neha Singh, Zoe Thuesmunn, Seesha R. Takagishi, Aubriana McEvoy, Coley Doolittle‐Amieva, Shailender Bhatia, Kelly G. Paulson, Ryan B. O'Malley, Carolyn L. Wang, Paul Nghiem
Published 2020-02-01

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

by Erin Jensen, Evan J Lipson, Martin A Cheever, Adil Daud, Brent A Hanks, Shailender Bhatia, Thomas Olencki, Kari Kendra, Mizuho Kalabis, William H Sharfman, Ragini R Kudchadkar, Philip A Friedlander, Sunil A Reddy, Brian C Boulmay, Adam Riker, Melissa A Burgess, Candice Church, Tomoko Akaike, Michi M Shinohara, Bob Salim, Blanca Homet Moreno
Published 2021-04-01